Overview Financials News + Filings Key Docs Charts Transactions Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Avalo Therapeutics, Inc. (CERC)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/05/2023 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 10/03/2023 |
8-K
| Shareholder Nominations Pursuant to Exchange Act Rule 14a-11 Interactive Data |
| 08/14/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 08/08/2023 |
8-K
| Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Interact... |
| 08/07/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 08/07/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/03/2023 |
8-K
| Quarterly results |
| 07/21/2023 |
8-K
| Quarterly results |
| 07/05/2023 |
4
| Persson Magnus (Director) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Granted 28,308 options to buy
@ $0.3552, valued at
$10.1k
|
|
| 07/05/2023 |
4
| Almenoff June Sherie (Director) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Granted 4,575 options to buy
@ $0.3552, valued at
$1.6k
|
|
| 06/29/2023 |
SC 13G/A
| Caissa Capital Management ltd. reports a 0% stake in Avalo Therapeutics, Inc. |
| 06/28/2023 |
4
| ARMISTICE CAPITAL, LLC (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Sold 2,746,138 shares
@ $0.6125, valued at
$1.7M
Sold 937,404 shares
@ $0.5194, valued at
$486.9k
|
|
| 06/09/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 2,984 shares
@ $3.4914, valued at
$10.4k
Bought 6,398 shares
@ $3.9271, valued at
$25.1k
Bought 5,044 shares
@ $4.1427, valued at
$20.9k
|
|
| 06/02/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 844 shares
@ $2.87, valued at
$2.4k
|
|
| 06/02/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ... |
| 05/30/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 2,000 shares
@ $2.77, valued at
$5.5k
Bought 671 shares
@ $2.867, valued at
$1.9k
|
|
| 05/24/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 3,481 shares
@ $3.0072, valued at
$10.5k
Bought 5,519 shares
@ $2.9622, valued at
$16.3k
|
|
| 05/17/2023 |
4
| Sullivan Christopher Ryan (CFO) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Granted 40,000 options to buy
@ $2.75, valued at
$110k
|
|
| 05/17/2023 |
4
| NEIL GARRY ARTHUR (CEO and Chairman of the Board) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Granted 100,000 options to buy
@ $2.75, valued at
$275k
|
|
| 05/16/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 2,285 shares
@ $2.45, valued at
$5.6k
Bought 1,715 shares
@ $2.5459, valued at
$4.4k
Bought 379 shares
@ $2.75, valued at
$1k
|
|
| 05/08/2023 |
4
| Caissa Capital Management ltd. (10% Owner) has filed a Form 4 on Avalo Therapeutics, Inc.|
Txns:
| Bought 15,000 shares
@ $2.7921, valued at
$41.9k
Bought 5,000 shares
@ $2.875, valued at
$14.4k
Bought 5,000 shares
@ $2.6216, valued at
$13.1k
|
|
| 05/04/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 05/04/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/04/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/04/2023 |
8-K
| Quarterly results |
| 05/03/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/28/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 04/27/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/25/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 04/24/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/21/2023 |
8-K
| Quarterly results |
| 04/19/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
|
|
|